MannKind to Showcase Pediatric and Adult Afrezza Data at ATTD 2026
Event summary
- MannKind to present new Afrezza data at ATTD 2026, including pediatric and adult studies.
- FDA review for Afrezza pediatric indication set for May 29, 2026.
- INHALE-1 study highlights dosing and titration patterns in pediatric patients.
- Afrezza is the only ultra-rapid-acting inhaled insulin approved for adults with diabetes.
The big picture
MannKind's presentation at ATTD 2026 underscores the growing interest in inhaled insulin as a non-invasive alternative to traditional injection methods. The potential FDA approval for pediatric use could significantly expand the market for Afrezza, addressing a critical unmet need in diabetes care. The company's focus on real-world dosing and titration patterns highlights its commitment to personalized diabetes management across different patient populations.
What we're watching
- Regulatory Approval
- Whether the FDA will approve Afrezza for pediatric use by the May 29, 2026 target date.
- Market Expansion
- How successful MannKind will be in positioning Afrezza as the first needle-free insulin option for pediatric patients.
- Clinical Efficacy
- The impact of the new data on clinician and patient adoption of Afrezza for both adult and pediatric diabetes management.
Related topics